The global single domain antibody platform market is booming, driven by increased healthcare R&D and the platforms’ efficacy in treating various diseases. This report projects market growth to US$ 86 million by 2034, with significant contributions from North America and East Asia. Leading players are driving innovation, but access to camelids, the primary source of these antibodies, remains a challenge.